

Product Sheet

H_CD40(TNFRSF5) Reporter Jurkat Cell Line


Catalog number: GM-C09520

Version 3.3.1.251215

CD40 is a key cell surface receptor in the TNF receptor superfamily, primarily found on B cells, dendritic cells, macrophages, and some endothelial cells. Its main role is to regulate immune responses by promoting B cell proliferation, differentiation, and antibody production. When it binds to its ligand CD40L (expressed by activated T cells), CD40 activates various signaling pathways that enhance immune function.

CD40 signaling occurs through multiple pathways activated upon CD40L binding, including NF- κ B, MAPK (ERK, JNK, p38 MAPK), and PI3K/Akt. This activation triggers biological responses such as cell proliferation, survival, cytokine secretion, and immune memory formation, making CD40 crucial for regulating immune responses and maintaining immune tolerance.

H_CD40(TNFRSF5) Reporter Jurkat Cell Line is a clonal stable Jurkat cell line constructed using lentiviral technology, constitutive expression of the CD40 gene, along with signal-dependent expression of a luciferase reporter gene. When CD40L binds to CD40, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can inhibit this signal transmission. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to CD40.



Specifications

Quantity	5E6 Cells per vial, 1 mL
Product Format	1 vial of frozen cells
Shipping	Shipped on dry ice
Storage Conditions	Liquid nitrogen immediately upon receipt
Recovery Medium	RPMI 1640 +10% FBS +1% P.S
Growth medium	RPMI 1640 +10% FBS +1% P.S+3.5 µg/mL Blastincidin+0.75 µg/mL Puromycin
Note	None
Freezing Medium	90%FBS+10% DMSO
Growth properties	Suspension
Growth Conditions	37°C, 5% CO ₂
Mycoplasma Testing	The cell line has been screened to confirm the absence of Mycoplasma species.
Safety considerations	Biosafety Level 2
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.

Materials

Reagent	Manufacturer/Catalogue No.
RPMI 1640	VivaCell/C3010-0500
Fetal Bovine Serum	ExCell/FSP500
Pen/Strep	Thermo/15140-122
Blasticidin	Genomeditech/ GM-040404
Puromycin	Genomeditech/ GM-040401
H_CD40L CHO-K1 Cell Line	Genomeditech/ GM-C35532
H_FCGR2B(CD32B) CHO-K1 Cell Line	Genomeditech/ GM-C16925
Human CD40L Protein; His Tag	Genomeditech/ GM-84919RP
Anti-H_CD40L hIgG1 Antibody(dapirolizumab)	Genomeditech/ GM-83977AB
Anti-H_CD40 hIgG1 Antibody(ravagalimab)	Genomeditech/ GM-86199AB
Anti-H_CD40 hIgG1 Antibody(APX005M)	Genomeditech/ GM-24025AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit	Genomeditech/ GM-040513

Figures




Figure 1 | Response to Human CD40L Protein. The H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well (96-well format) was stimulated with serial dilutions of Human CD40L Protein (Cat. GM-84919RP) in assay buffer (RPMI 1640 + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [71.7]. Data are shown by drug mass concentration.




Figure 2 | Response to Human CD40L Protein. The H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well (96-well format) was stimulated with serial dilutions of Human CD40L Protein (Cat. GM-84919RP) in assay buffer (RPMI 1640 + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [71.7]. Data are shown by drug molar concentration.




Figure 3 | Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. [GM-83977AB](#)) was incubated with 100 ng/well of Human CD40L Protein (Cat. [GM-84919RP](#)) for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). After pre-incubation, add the mixture to the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a density of 1E5 cells/well in a 96-well format, and incubate for 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [61.2]. Data are shown by drug mass concentration.




Figure 4 | Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. [GM-83977AB](#)) was incubated with 100 ng/well of Human CD40L Protein (Cat. [GM-84919RP](#)) for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). After pre-incubation, add the mixture to the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a density of 1E5 cells/well in a 96-well format, and incubate for 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit

(Genomeditech). The results indicated maximum blocking folds of approximately [61.2]. Data are shown by drug molar concentration.




Figure 5 | Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of the Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. [GM-83977AB](#)) was incubated with 1E4 cells/well of the H_CD40L CHO-K1 Cell Line (Cat. [GM-C35532](#)) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [45.2]. Data are shown by drug mass concentration.




Figure 6 | Response to Anti-H_CD40L hIgG1 Antibody(dapirolizumab). Serial dilutions of the Anti-H_CD40L hIgG1 Antibody(dapirolizumab) (Cat. [GM-83977AB](#)) was incubated with 1E4 cells/well of the H_CD40L CHO-K1 Cell Line (Cat. [GM-C35532](#)) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the

H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [45.2]. Data are shown by drug molar concentration.




Figure 7 | Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). Serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. [GM-86199AB](#)) was incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the Human CD40L Protein (Cat. [GM-84919RP](#)) at a concentration of 50 ng/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [14.3]. Data are shown by drug mass concentration.




Figure 8 | Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). Serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. [GM-86199AB](#)) was incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour in assay buffer (RPMI 1640 + 1% FBS + 1% P.S). Subsequently, the Human CD40L Protein (Cat. [GM-84919RP](#)) at a concentration of 50 ng/well was added, and the coculture proceeded for an additional 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [14.3]. Data are shown by drug molar concentration.




Figure 9 | Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). H_CD40L CHO-K1 Cell Line (Cat. [GM-C35532](#)) was seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. [GM-86199AB](#)) were incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour, and then added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity is then measured

using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [41.3]. Data are shown by drug mass concentration




Figure 10 | Response to Anti-H_CD40 hIgG1 Antibody(ravagalimab). H_CD40L CHO-K1 Cell Line (Cat. [GM-C35532](#)) was seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of the Anti-H_CD40 hIgG1 Antibody(ravagalimab) (Cat. [GM-86199AB](#)) were incubated with 1E5 cells/well of the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) in a 96-well plate for 1 hour, and then added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [41.3]. Data are shown by drug molar concentration.




Figure 11 | Response to Anti-H_CD40 hIgG1 Antibody(APX005M). The H_FCGR2B (CD32B) CHO-K1 Cell Line (Cat. [GM-C16925](#)) and the CHO-K1 Cell Line were seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of Anti-H_CD40 hIgG1 Antibody(APX005M) Cat. [GM-24025AB](#)) and the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells per well were added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity was

measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [50.5 and 6.7]. Data are presented based on drug mass concentration.




Figure 12 | Response to Anti-H_CD40 hIgG1 Antibody(APX005M). The H_FCGR2B (CD32B) CHO-K1 Cell Line (Cat. [GM-C16925](#)) and the CHO-K1 Cell Line were seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of Anti-H_CD40 hIgG1 Antibody(APX005M) Cat. [GM-24025AB](#)) and the H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells per well were added to the pre-seeded cells. The mixture was incubated for an additional 6 hours. Firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [50.5 and 6.7]. Data are presented based on drug molar concentration.




Figure 13 | The passage stability of response to Human CD40L Protein. The passage 4, 14 and 24 of H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) at a concentration of 1E5 cells/well (96-well format) were stimulated with serial dilutions of Human CD40L Protein (Cat. [GM-84919RP](#)) in assay buffer (RPMI 1640 + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). Data are shown by drug mass concentration.




Figure 14 | H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) was determined by flow cytometry using Anti-H_CD40 hIgG1 Antibody(APX005M) (Cat. [GM-24025AB](#)).




Figure 15 | H_CD40(TNFRSF5) Reporter Jurkat Cell Line (Cat. GM-C09520) was determined by flow cytometry using Anti-H_CD40L hIgG1 Antibody(dapirolizum) (Cat. [GM-83977AB](#)).

Cell Recovery

Recovery Medium; RPMI 1640 +10% FBS +1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

- Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
- Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

- d) Resuspend cell pellet with the recommended complete medium. And dispense the suspension into 1 - 2 T-25 culture flasks.
- e) Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90%FBS+10% DMSO

- a) Centrifuge at 176 x g for 3 minutes to collect cells.
- b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
- c) Aliquot 1 mL into each vial.
- d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640 +10% FBS +1% P.S+3.5 µg/mL Blastincidin+0.75 µg/mL Puromycin

Approximately 48-72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics. If cells are not passaged within 48 hours, it is recommended to add some fresh recovery medium and place the flask horizontally.

- a) When the cell density reaches 1.5 - 2E6 cells/mL, subculture the cells. Do not allow the cell density to exceed 2E6 cells/mL.
- b) It is recommended to use T-25 flasks for subculturing.
- c) These cells are suspension cells, and it is recommended to use the "half-medium change" method to maintain optimal cell conditions during passaging.
- d) During passaging, you can directly add fresh growth medium to the culture flask, gently pipette to resuspend the cells, and then transfer the cell suspension to a new T-25 flask for continued culture.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 3E5 and 1E6 viable cells/mL.

Medium Renewal: Every 2 to 3 days

Notes

- a) These cells are sensitive to density, so please ensure that the cell density is maintained within an appropriate range during culture and subculturing.
- b) During the first passage, pay attention to the nutrient supply; if not subculturing, make sure to add fresh recovery medium every other day as needed.

Related Products

CD40:CD40L	
H_CD40(TNFRSF5) Reporter 293 Cell Line	Cynomolgus_CD40 CHO-K1 Cell Line

Cynomolgus_CD40L CHO-K1 Cell Line	H_CD40(TNFRSF5) CHO-K1 Cell Line
H_CD40(TNFRSF5) HEK-293 Cell Line	H_CD40L CHO-K1 Cell Line
H_CD40L HEK-293 Cell Line	Rabbit_CD40L NIH-3T3 Cell Line
Anti-CD40L hIgG1 Reference Antibody (Frebio)	Anti-H_CD40 hIgG1 Antibody(APX005M)
Anti-H_CD40 hIgG1 Antibody(ravagalimab)	Anti-H_CD40L hIgG1 Antibody(dapirolizumab)
Anti-H_CD40L hIgG1 Antibody(frexalimab)	
Biotinylated Human CD40 Protein; His-Avi Tag	Cynomolgus CD40 Protein; His Tag
Human CD40 Protein; His Tag	Human CD40L Protein; His Tag
IFN- α	
IFN α Reporter HEK-293 Cell Line	IFN α Reporter MDCK Cell Line
IFN α Reporter THP1 Cell Line	
BCMA:BAFFR:TACI	
H_BAFFR Jurkat Blockade Reporter Cell Line	H_BAFFR Reporter Cell Line
H_BCMA Reporter Cell Line	H_TACI Reporter Cell Line
Cynomolgus_BCMA CHO-K1 Cell Line	Cynomolgus_BCMA HEK-293 Cell Line
H_BCMA CHO-K1 Cell Line	H_BCMA HEK-293 Cell Line
Anti-BAFF hIgG1 Antibody(belimumab)	Anti-BAFFR hIgG1 Antibody(inalumab)
Anti-BCMA hIgG1 Antibody(Belantamab)	Anti-BCMA hIgG1 Antibody(SEA-BCMA)
Anti-BCMA hIgG4 Antibody(BCMB69)	
Biotinylated Human BAFF Protein; His-Avi Tag	Biotinylated Human BCMA Protein; His-Avi Tag
Cynomolgus BAFF Protein; His Tag	Cynomolgus BCMA Protein; hFc Tag
Cynomolgus BCMA Protein; His Tag	Human APRIL Protein; hFc Tag
Human BAFF Protein; His Tag	Human BCMA Protein; hFc Tag
Human BCMA Protein; His Tag	Mouse BAFF Protein; His Tag
BDCA2(CLEC4C)	
H_BDCA2 Reporter Jurkat Cell Line	Cynomolgus_BDCA2 CHO-K1 Cell Line
Cynomolgus_BDCA2 Jurkat Cell Line	H_BDCA2 CHO-K1 Cell Line
H_BDCA2 HEK-293 Cell Line	H_BDCA2 Jurkat Cell Line
Anti-H_BDCA2 hIgG1 Antibody(Litifilimab)	
Cynomolgus BDCA2 Protein; His Tag	Human BDCA2 Protein; His Tag

License Agreement:

By purchasing and using this cell line product, the user voluntarily agrees to accept and abide by the following policies:

- This cell line product is restricted to research use only and shall not be used for any commercial purposes.
- This product is strictly prohibited from being used in the diagnosis or treatment of human or animal diseases, and shall not be directly used in experiments involving humans.

- Users and their contractors engaged for their benefit may use this material and its derivatives only within the agreed research scope; modification of the material is not permitted, nor may it be distributed, sold, transferred, or otherwise provided to any other entity (including affiliates).
- If use beyond the above scope is required, prior written permission from Genomeditech (Shanghai) Co.,Ltd. must be obtained. For details, please contact Genomeditech (Shanghai) Co.,Ltd.

Genomeditech